Sat.Oct 15, 2022 - Fri.Oct 21, 2022

article thumbnail

How to evolve artificial intelligence models alongside societal needs

MedCity News

As society becomes more open to and reliant on these tools, it is the responsibility of technology companies, especially those tasked with assisting people’s mental health, to build and maintain artificial intelligence and machine learning models that adapt alongside societal needs.

145
145
article thumbnail

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

In recent years there has been significant development within the cell therapy field, as chimeric antigen receptor (CAR) T-cell therapy demonstrated an ability to transform the treatment of patients with haematological malignancies. Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Lilly agrees to acquire gene therapy developer Akouos for $610m

Pharmaceutical Technology

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 for each share in cash. The deal comprises an acquisition value of $12.50 for each share in cash payable at closing along with one non-tradeable contingent value right per share (CVR) of up to another $3 in cash.

article thumbnail

Frontiers Health 2022 – day 2

pharmaphorum

And the LIVE coverage continues as we head into Day Two… This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that work for customers’ (moderated by Healthware Group’s global head of digital strategy and customer engagement Yannick Valenti), as well as the masterclass ‘How to maximise learning science to affect behaviour change’ with Meducate Global’s president, Lawrence Sherman, and MD of Healthware MedComms & SWM, Francis M

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Eyenuk raises $26M for diabetic retinopathy screening tech

MedCity News

Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company’s AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.

133
133
article thumbnail

CHMP recommends Pluvicto® for treating advanced prostate cancer

European Pharmaceutical Review

Novartis announced that The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Pluvicto ® radioligand therapy for treatment of patients with prostate cancer. Pluvicto combines a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope (in this case lutetium-177).

Medicine 120

More Trending

article thumbnail

Bayer extends elinzanetant trials to include breast cancer

pharmaphorum

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. Elinzanetant is already being tested in the OASIS trials for VMS associated with menopause – an indication in which Bayer is in a head-to-head race with Astellas and its fezolinetant drug candidate – and breast cancer could represent a sizeable additional patient population for the drug.

Patients 107
article thumbnail

Cancer drug biotech Enliven shifts to reverse to move forward as a public company

MedCity News

Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.

Biopharma 128
article thumbnail

He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma

PharmaVoice

Bristol Myers Squibb’s senior principal scientist Ryan Moslin shares why his team was built for success and how they ushered a potential psoriasis blockbuster through discovery.

Pharma 98
article thumbnail

Fluorescence Imaging System Illuminates Tumor Depth

Medgadget

Medical researchers at Washington University School of Medicine in St. Louis have developed a fluorescence imaging technique that allows them to illuminate a tumor in situ and calculate its depth below the surface of the body. The technique could assist surgeons in accurately removing a tumor and successfully excising an appropriate margin of healthy tissue to reduce the chances of tumor recurrence.

Medicine 105
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Frontiers Health 2022 – day 1

pharmaphorum

Frontiers Health 2022 in Milan is LIVE! Opening Day One will be Healthware Group’s CEO and founder Roberto Ascione and WTF Health’s founder and host Jessica DaMassa. The day’s keynote addresses will include ‘The H is for humanity’ by MD of Taliossa Tony Estrella and founder and trustee of Rachel’s House Lynna Chandra, as well as ‘Creative disruption in delivering novel VR solutions in pain: evidence, teamwork, and delivery’ by Christopher Eccleston, professor of medical psychology at the U

article thumbnail

How to improve data literacy within healthcare organizations

MedCity News

Healthcare organizations must ensure they have a data-literate workforce that is confident in using the data and is empowered in using it to make decisions. Here are some best practices that hospitals can implement to better empower their employees to make data-driven decisions.

article thumbnail

Novo Nordisk acquires Forma Therapeutics for $1.1bn

Pharmaceutical Technology

Novo Nordisk has concluded the acquisition of all outstanding shares of common stock of clinical-stage biopharmaceutical company Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn. In September, Novo Nordisk entered a definitive agreement to acquire Forma. With the conclusion of the merger, Forma became Novo Nordisk’s fully-owned subsidiary. .

article thumbnail

Screening App to Diagnose Parkinson’s, COVID-19 from Voice

Medgadget

Researchers at RMIT University in Melbourne, Australia, have developed an app that is intended to provide early diagnosis for Parkinson’s disease and severe COVID-19. The artificial intelligence-powered technology works by analyzing voice recordings, having previously been trained to recognize the vocal hallmarks of these diseases by listening to recordings of patients.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Text message therapy for depression works in young adults

pharmaphorum

Young adults with depression have been treated effectively with a cognitive behavioural therapy (CBT) course – delivered via text message – in a pilot study conducted by researchers in the US. The trial looked at a four-week CBT course adapted from a face-to-face programme to work via text messages, followed by a four-week follow-up period, in around 100 young adults in the US with at least one symptom of moderate depression and no recent history of antidepressant therapy.

article thumbnail

NeuroFlow raises $25M to scale behavioral health integration tech

MedCity News

NeuroFlow, a Philadelphia-based provider of behavioral health integration software, recently raised $25 million in growth capital. The startup differentiates itself from the sea of mental health-focused startups in the digital health world because of its ability to combine effective patient engagement technology with decision support tools for clinical staff, according to COO Adam Pardes.

Patients 132
article thumbnail

Indegene Acquires CultHealth, a Full Service, Healthcare Marketing Agency to Elevate Brand Experience

PharmExec

The acquisition by ILSL Inc., a subsidiary of Indegene Private Limited, augments Indegene’s commercialization portfolio spanning drug discovery and development to marketing and sales, adding brand strategy, market development capabilities, and patient engagement platforms.

article thumbnail

EC approves CAR T-Cell therapy for B-cell lymphoma

European Pharmaceutical Review

Kite announced that the European Commission (EC) has approved the use of cell therapy Yescarta ® for treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), who relapse within 12 months or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the Phase III ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus standard of care (SOC) in this patient population.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Bringing the promise of immunotherapy to a broader population

pharmaphorum

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their discovery of cancer therapy through inhibition of negative immune regulation, it shone a light on decades of research into recruiting the immune system to fight cancer. Their success led to the discovery of an entirely new principle for cancer therapy – the field of immuno-oncology – one that is now a mainstay of cancer treatment, changing the way these diseases can be managed.

article thumbnail

Here’s 40 years of cardiac advancements that few know about

MedCity News

With so much supporting data and real-world success, it is time for catheter ablation to become a routine treatment option for patients suffering from arrhythmias.

Patients 134
article thumbnail

J&J reveals just how much economic turbulence is affecting Big Pharma

PharmaVoice

The healthcare giant showed pharmaceutical gains, but that's no thanks to the economic environment of persistent inflation and a strong U.S. dollar.

Pharma 105
article thumbnail

Immunotherapy shows benefits for hospitalised COVID-19 patients

European Pharmaceutical Review

Apogenix , a biopharmaceutical company developing next generation immunotherapeutics, announced that asunercept showed statistically significant benefits for hospitalised COVID-19 patients in the ASUNCTIS trial. Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. It is being developed for the treatment of solid tumours, haematological malignancies and viral infections such as COVID-19.

Patients 101
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

GSK continues campaign for greater adult immunisation coverage

pharmaphorum

The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. Ben Hargreaves examines the reasons supplied by the survey and why GSK is invested in the answers. The emergence of COVID-19 meant that public awareness around vaccination and its importance in fighting the spread of infectious disease has increased rapidly.

article thumbnail

Report: Insurers from 55 countries expect healthcare benefit costs to jump 10% in 2023

MedCity News

The 10% increase is the largest in almost 15 years, the Willis Towers Watson survey found. Most of the insurers, or 75%, blamed the overuse of care for the rise in medical costs.

Insurance 124
article thumbnail

FDA-Approved At-Home Spirometer: Interview with Charvi Shetty, Co-Founder and CEO at Aluna

Medgadget

The COVID-19 pandemic has put lung health firmly in our minds. For those with chronic lung diseases, such as asthma and COPD, an important way to keep track of lung health is to use a spirometer to measure how well air can move in and out of the lungs during forced breathing. However, patients would typically attend with a lung specialist to perform this test.

Doctors 93
article thumbnail

First patient receives novel, potentially cancer-stopping pill

European Pharmaceutical Review

City of Hope , one of the largest cancer research and treatment organisations in the US, announced that the first patient to receive novel cancer medicine AOH1996, is doing well. The Phase I clinical trial is open at City of Hope Los Angeles. Its objective is to determine the maximum tolerated dose of the investigational pill, AOH1996, and to evaluate the medicine for preliminary efficacy.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

How the Digital Patient Experience is Shaping the Future of Pharma

pharmaphorum

From diagnosis to treatment and ongoing condition management, the patient journey is becoming an increasingly digitised one – a process which has been massively accelerated by the Covid pandemic and has significant implications for pharma & their patients vs. their customers. Join us on Monday 7 th November at 12:30 GMT / 13:30 CET / 7:30 am EDT as panellists focus on how this new paradigm is shaping both the industry’s omnichannel engagement and the patient care journey, from patient identi

article thumbnail

Why care at home belongs in health equity strategies

MedCity News

Providers can’t treat what they can’t detect. But encountering patients in the context of their home and family puts issues of equity and access into sharp contrast, allowing case managers to connect patients to ongoing resources for SDoH or transportation.

article thumbnail

Scientists Teach Neurons to Play Pong

Medgadget

Scientists at Cortical Labs in Melbourne, Australia, along with international collaborators, have developed “DishBrain”, which is essentially a collection of neurons in a dish that have demonstrated learning and, incredibly, can play the classic computer game Pong. The findings could create exciting new opportunities to understand the human brain, model neurological diseases, and test the effects of medications on the brain more easily.

article thumbnail

What’s keeping pharma leaders up at night

PharmaVoice

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

Pharma 111
article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.